Literature DB >> 2383200

Ocular findings in oculodermal melanocytosis.

C Teekhasaenee1, R Ritch, U Rutnin, N Leelawongs.   

Abstract

We examined 194 patients with oculodermal melanocytosis. Dermal involvement alone was present in 67 (34.5%) patients, while 12 (6.2%) had only ocular involvement. The remaining 115 (59.3%) patients had both ocular and dermal pigmentation. Dermal hyperpigmentation in the combined distribution of the ophthalmic and maxillary divisions of the trigeminal nerve and hyperpigmentation of the nasal or buccal mucosa were closely associated with ocular involvement. Ocular hyperpigmentation most commonly involved the episclera. Associated ocular findings included elevated intraocular pressure with or without glaucoma (10.3%), uveitis (2.6%), cataract (1%), asymmetric cupping of the optic nerve head unassociated with glaucoma (9.8%), and orbital melanoma (0.5%). The most serious complication of oculodermal melanocytosis is malignant transformation, while glaucoma appears to be the more common one. Patients with oculodermal melanocytosis and ocular hyperpigmentation should be followed up at regular intervals for the development of either of these complications.

Entities:  

Mesh:

Year:  1990        PMID: 2383200     DOI: 10.1001/archopht.1990.01070100070037

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  20 in total

Review 1.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  Atypical midface tumor complicating nevus of ota.

Authors:  René Patzwahl; Klara Landau; Spyros S Kollias
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

3.  Choroidal malignant melanoma in association with oculodermal melanocytosis in a black patient.

Authors:  A F Bordon; M L Wray; R Belfort; I W McLean; M Burnier
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

4.  [Rare presentation of a scleral nevus with progression in size].

Authors:  E J Schmitz; M C Herwig; F G Holz; E Bierhoff; K U Löffler
Journal:  Ophthalmologe       Date:  2017-08       Impact factor: 1.059

5.  GNA11 Mutation as a Cause of Sturge-Weber Syndrome: Expansion of the Phenotypic Spectrum of Gα/11 Mosaicism and the Associated Clinical Diagnoses.

Authors:  Satyamaanasa Polubothu; Lara Al-Olabi; Maria Carmen Del Boente; Alisha Chacko; Georgios Eleftheriou; Mary Glover; David Jiménez-Gallo; Elizabeth A Jones; Debra Lomas; Regina Fölster-Holst; Samira Syed; Monika Tasani; Anna Thomas; Martin Tisdall; Antonio Torrelo; Sarah Aylett; Veronica A Kinsler
Journal:  J Invest Dermatol       Date:  2019-12-12       Impact factor: 8.551

6.  Prevalence of ocular and oculodermal melanocytosis in Spanish population with uveal melanoma.

Authors:  E Carreño; M A Saornil; C Garcia-Alvarez; F Lopez-Lara; J M De Frutos-Baraja; A Almaraz
Journal:  Eye (Lond)       Date:  2011-10-21       Impact factor: 3.775

Review 7.  An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota).

Authors:  Solmaz Abdolrahimzadeh; Damiano Maria Pugi; Priscilla Manni; Clemente Maria Iodice; Federico Di Tizio; Flavia Persechino; Gianluca Scuderi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-19       Impact factor: 3.535

8.  Episcleral melanoma as a complication of ocular melanocytosis.

Authors:  Curtis R Louwagie; Keith H Baratz; Jose S Pulido; Diva R Salomão; Dustin L Dierks
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

9.  Malignant melanoma of the optic nerve head in a case of oculodermal melanocytosis.

Authors:  M Unal; I Gunalp; A Deery; I Durak; S Erekul; O Bulay
Journal:  Br J Ophthalmol       Date:  1992-05       Impact factor: 4.638

10.  Role of q-switched nd:yag laser in nevus of ota: a study of 25 cases.

Authors:  Shivangi Sharma; Abhijeet Kumar Jha; Sambeet Kumar Mallik
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.